Loading clinical trials...
Loading clinical trials...
A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Conditions
Interventions
Lunsekimig
Placebo
Locations
166
United States
Chandler Clinical Research Trials- Site Number : 8400025
Chandler, Arizona, United States
Pulmonary Associates - Phoenix - East Bell Road- Site Number : 8400114
Phoenix, Arizona, United States
Epic Medical Research - Surprise- Site Number : 8400096
Surprise, Arizona, United States
IMAX Clinical Trials- Site Number : 8400109
La Palma, California, United States
Long Beach Research Institute- Site Number : 8400027
Long Beach, California, United States
Downtown L.A. Research Center- Site Number : 8400009
Los Angeles, California, United States
Start Date
September 16, 2025
Primary Completion Date
November 27, 2029
Completion Date
January 22, 2030
Last Updated
April 21, 2026
NCT05746039
NCT07509606
NCT07477600
NCT05878769
NCT06717659
NCT07274631
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610contact-us@sanofi.comLead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions